SPANISH HEAD AND NECK CANCER COOPERATIVE GROUP (TTCC)

Slides:

Advertisements

Similar presentations

Neoadjuvant Chemotherapy in Locally Advanced Squamous Cell Cancer of Head and Neck Mei Tang, MD.

Advertisements

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

Statements on Head and Neck Cancer 2006 Primary Radiochemotherapy Arlene A. Forastiere, M.D. Johns Hopkins University School of Medicine Department of.

ANDREW NG PRINCE OF WALES HOSPITAL Role of primary chemoradiation in esophageal carcinoma.

Squamous Cell H&N Cancer Hypopharynx Therapeutic Approach Ricardo Hitt MD, PhD Hospital Universitario 12 Octubre MADRID STATEMENTS 2008.

Postoperative Radiation for Oral Cavity Squamous Cell Carcinoma: The EP.

Dr. LP Si Tseung Kwan O Hospital. Introduction CA stomach is the 4 th most commonly diagnosed malignancy worldwide 2 nd most common cause of cancer-related.

Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.

Upper gastrointestinal cancers

Drug Treatment of Metastatic Breast Cancer

IMRT for the Treatment of Anal Cancer Kristen O’Donnell, MS3 December 12, 2007.

Van Cutsem E et al. ASCO 2009; Abstract LBA4509. (Oral Presentation)

INT Translational research in head and neck cancer: preoperative chemotherapy in oral cavity cancer based on disease molecular profiling. Paolo Bossi MSO.

Eric Van Cutsem Head, Digestive Oncology, University Hospital Gasthuisberg and Professor of Internal Medicine, University of Leuven, Belgium Published.

Recent Advances in Head and Neck Cancer Robert I. Haddad, M.D., and Dong M. Shin, M.D. The NEW ENGLAND JOURNAL of MEDICINE N Engl J Med 2008;359:

Treatment Regimens of HER2+ Adjuvant Patients (Actuals) Source: Genentech ASCO 2005 (data release) Nov 2006 (Approval)

Poster # 18, abstract # 4530 Long term results of a phase III study investigating chemoradiation with and without surgery in locally advanced squamous.

Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.

The Role of Preoperative Approaches in Localized Gastro Esophageal Cancers David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan-Kettering.

Head & Neck Ca. (Epithelial tumors) Mohamad KADRI. MD. Clinical oncology. Medical director of AlBerouni University Hospital President of Syrian Association.

Head and Neck Cancer CCO Independent Conference Coverage of the 2006 Annual Meeting of the American Society of Clinical Oncology* *CCO is an independent.

GCIG Rare Tumor Working Group Prague, CZ, October, 2010 Chair: Isabelle Ray-Coquard Co-Chair: David M. Gershenson.

Empowering induction therapy for locally advanced head and neck cancer A. Argiris1* & M. V. Karamouzis2 1Division of Hematology–Oncology, Department of.

Esophageal Cancer: A Critical Evaluation of Systemic Second-Line Therapy Christiane Maria Rosina Thallinger, Markus Raderer, and Michael Hejna J Clin Oncol.

종양혈액내과 R4 고원진 / pf. 김시영 Rectal cancer : state of the art in 2012 Curr Opin Oncol 2012, 24:441–447.

NEW RADIOTHERAPY AND CHEMORADIOTHERAPY APPROACHES FOR NON–SMALL-CELL LUNG CANCER Joseph K. Salama and Everett E. Vokes J Clin Oncol 31: R4 신재령.

Department of Hemato-Oncology MGR review.  Epithelial carcinoma of the head and neck  arised from the mucosal surfaces in the head and meck area  squamous.

RANDOMIZED PHASE II STUDY OF NABPACLITAXEL, IN RECURRENT ADVANCED OR METASTATIC CERVICAL CANCER MITO CER-NAB Enrica Mazzoni, MD Medical Oncology & Breast.

Recent Advances in NSCLC Treatment

Head and Neck Cancer December 6,2016 Uzma Athar, MD.

Esophageal Cancer Updates.

Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)

Short-term outcome of neo-adjuvant chemotherapy

Management of metastatic and recurrent head and neck cancer

Treatment options for HPV+ disease

Azienda Ospedaliero Universitaria Policlinico Modena

Post - ASCO 2007 Unresectable Stage IIIA/B NSCLC

Volume 16, Issue 2, Pages (February 2015)

Results of Definitive Radiotherapy in Anal Canal Carcinoma

A Single-Arm Phase IIIb Study of Pertuzumab and Trastuzumab with a Taxane as First-Line Therapy for Patients with HER2-Positive Advanced Breast Cancer.

Phase II Study of Docetaxel (D) and Oxaliplatin (O) in Recurrent Metastatic Transitional Cell Carcinoma of the Bladder Davar D1, Appleman LA1, Friedland.

SWAG SSG Head and Neck Cancer Meeting

ESPAC-4: Adjuvant Gemcitabine/ Capecitabine Improves 5-Yr Survival vs Gemcitabine Alone in Resected Pancreatic Ductal Carcinoma CCO Independent Conference.

Residents - Educational Conference October 25, 2013

Systemic treatment of advanced cutaneous squamous and basal cell carcinomas.

Evolving Paradigms in Recurrent/Metastatic SCCHN

Metastatic HER2+ Breast Cancer: Resistance

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

SWAG SSG Urology Meeting

A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous.

Baselga J et al. SABCS 2009;Abstract 45.

Best Practices in Lymph Node Mapping and Localization: Melanoma

INDUCTION CHEMOTHERAPY

Surgery vs. primary radiotherapy in early-stage oropharyngeal cancer

Grupo Español de Investigación en Sarcomas

ACT II: The Second UK Phase III Anal Cancer Trial

Locally Advanced Lung Cancer

Capecitabine versus 5-fluorouracil-based (neo-)adjuvant chemoradiotherapy for locally advanced rectal cancer: safety results of a randomized phase III.

Treatment of Locally Advanced Pancreatic Cancer

Neoadjuvant Adjuvant Curative Palliative

Practical Guidance on the Management of Pan-Negative NSCLC

Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated.

Cancer specialty specific objectives

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

Treatment of Stage III Non-small Cell Lung Cancer

Kaplan–Meier curve for progression-free survival for gefitinib versus doublet chemotherapy in three phase III trials in first-line nonsmall cell lung cancer.

Phase I Study of Induction Chemotherapy and Concomitant Chemoradiotherapy with Irinotecan, Carboplatin, and Paclitaxel for Stage III Non-small Cell Lung.

A–J, Pretreatment (A) and post–cycle 3 (B) computed tomographic imaging for patient A–J, Pretreatment (A) and post–cycle 3 (B) computed tomographic.

A Randomized Phase II Trial Assessing in Advanced Non-small Cell Lung Cancer Patients with Stable Disease after Two Courses of Cisplatin-Gemcitabine an.

Presentation transcript:

SPANISH HEAD AND NECK CANCER COOPERATIVE GROUP (TTCC)

February st International Head & Neck Symposium 2001 Cooperative Group with 15 members National Symposiums TTCC 2005_Barcelona 2007_Salamanca 2009_Zaragoza 2011_Valencia

ACTIVITIES TRAINING DISCLOSURE PREVENTION DIAGNOSIS TREATMENT TRAINING DISCLOSURE PREVENTION DIAGNOSIS TREATMENT

Clinical Trials Closed: 5 Opened: 3 Approved by the CEC: 2 Over patients PREVENTION, PRESERVATION, LOCOREGIONAL AND METASTASIC

QTI / NEW MEDICAMENTS MOLECULAR TARGETS SURGERY RDT QTRDT RT-E RDT QTRDT RT-E SUPPORT BASIC AND TRASLACIONAL INVESTIGATION

A randomized phase II, multicenter trial of induction with Cisplatin/ Docetaxel verus Cisplatin/5-fluorouracil for patients with locally advanced head and neck carcinoma. February 2000 and July 2001, 84 patients TAX-ES-202. Published in Eur J Cancer Jun;41(9): A randomized, multicenter phase III trial comparing induction chemotherapy with Cisplatin/5-FU (PF) or Docetaxel/Cisplatin/5-FU (TPF) plus chemotherapy (CRT) versus CRT alone as fisrt-line treatment of unresectable locally advanced head and neck cancer. XRP6976F / COMUNICACIÓN ORAL ASCO Phase II study of combination Cetuximab and weekly Paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck ERBITAX. ASCO Pending of publication Phase II study of Capecitabine as palliative treatment for patients with squamous head and neck cancer with locoregional and/or metastatic relapse after previous Platinium-based treatment. XEL-CYC-TTCC. POSTER ASCO Pending of publication A single arm, multicenter, phase II trial to evaluate the combination of cetuximab plus taxotere (T), cisplatin (P) and 5- fluorouracil (F) (TPF) as induction chemotherapy in patients (pts) with unresectable squamous cell carcinoma of the head and neck. NEO-TPFE-TTCC. Póster discusión ASCO Preliminar results A randomized, multicenter phase III trial comparing induction chemotherapy with Cisplatin/5-FU (PF) or Docetaxel/Cisplatin/5-FU (TPF) plus chemotherapy (CRT) versus CRT alone as fisrt-line treatment of unresectable locally advanced head and neck cancer. XRP6976F / COMUNICACIÓN ORAL ASCO Pending of publication

Open Studies An Open Label Randomized, Multi-Centre Phase III Trial of TPF Chemotherapy Plus Concomitant Treatment With Cisplatin and Conventional Radiotherapy Versus TPF Chemotherapy Plus Concomitant Cetuximab and Conventional Radiotherapy in Locally Advanced, Un-resectable Head and Neck Cancer. TTCC (ClinicalTrials.gov Identifier: NCT ) A Phase II Trial With Radiotherapy Plus Cetuximab to Evaluate Specific Survival Free of Laryngectomy in Patients With Resectable and Locally Advanced Larynx Cancer, After Treatment With TPF Chemotherapy. TTCC ( ClinicalTrials.gov Identifier: NCT ) An Open Label Randomized, Phase III Trial With Erlotinib (Tarceva®) as Maintenance Treatment in Patients With Operated Squamous Cell Carcinoma of the Head and Neck and treated with Chemo-radiotherapy or Radiotherapy with Curative Purposes. ML20294 (Nº EudraCT: )

PANITUMUMAB IN METASTASICS IN LOCALLY ADVANCED LAPATINIB THYROIDS CANCER NASOPHARYNGEAL CANCER